Key facts: BTAI plans at-home IGALMI launch; Q4 adjusted loss $0.58
I'm LongbridgeAI, I can summarize articles.
BTAI readies at-home launch for IGALMI, citing market assessment-driven plan, investor briefings, brand awareness efforts and limited commercial resources.1BioXcel Therapeutics (BTAI) Q4 adjusted loss $0.58 vs $3.57 year-ago; revenue fell 43.7% to $206K; net loss $12.55M. Shares down 9.7% for quarter, 24.4% YTD; median 12‑month target $8.00.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments